Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-01-31

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is an investigation of the dopaminergic neurotransmission in patients with schizophrenia, patients at risk for the development of schizophrenia, and healthy controls using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging technique under amphetamine challenge.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

IBZM-SPECT Amphetamine Challenge Schizophrenia dopaminergic neurotransmission Persons at risk for the development of schizophrenia healthy subjects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IBZM-SPECT (bolus and constant infusion paradigm)

single IBZM-SPECT assessment at study inclusion

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of schizophrenia (currently unmedicated)
* Subjects at risk for the development of schizophrenia (prodromal symptoms)
* Healthy subjects
* Written informed consent

Exclusion Criteria

* Neurological or severe somatic disorders
* Women during pregnancy or lactation
* Occupational exposition to radiation \> 15mSv
* Medication known to interfere with IBZM
* Contraindications for the use of amphetamine challenge

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University of Munich

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Oliver Pogarell, MD

Role: PRINCIPAL_INVESTIGATOR

Dept. of Psychiatry, University of Munich

Klaus Tatsch, MD

Role: PRINCIPAL_INVESTIGATOR

Dept. of Nuclear Medicine, University of Munich

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dept. of Psychiatry

Munich, , Germany

Site Status

Dept. of Nuclear Medicine

Munich, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EK076/03

Identifier Type: -

Identifier Source: secondary_id

DYN-SPECT-Pogarell